Year 2011 Vol. 19 No 5




Objectives. To estimate both efficacy and safety of bevacizumab intravitreal injection in patients with refractory diabetic macular edema.
Methods. Randomized trial of 160 eyes of 82 patients with refractory diabetic macular edema has been carried out. Patients in whom intravitreal injections of 1, 25 mg in 0, 05 ml of bevacizumab were done composed the main group (61 eyes). In the given group ophthalmological examinations were performed on the 2nd, 4th, 8th, 12th, 16th, 20th and 24th weeks of observation and further they were carried out every 3 months up to the end of the observation period. Control group of patients (99 eyes) were subjected to repeated sessions of focal laser coagulation with ophthalmological examinations before the procedure.
Results. Clinical trials have determined that a new method of treatment reliably permits to decrease central thickness of the retina and to increase visual acuity in comparison with control group of patients
Conclusions. Intravitreal injection of bevacizumab is an effective and safe method of patients with refractory diabetic macular edema treatment; it permits in short time to reduce the retina edema, to stabilize or to increase patients, visual acuity and it also contributes to regression of the retina neovascularization.

Keywords: diabetic macular edema, inhibitors of vascular endothelial growth factor, antiangiogenic therapy
p. 112 117 of the original issue
  1. 1.Otani, T. Patterns of diabetic macular oedema with optical coherence tomograph / T. Otani, S. Kishi, Y. Maruyama // Am. J. Ophthalmol. 1999. Vol. 127. P. 688-693.
  2. 2.Photoreceptor function in eyes with macular oedema / C. W. T. A. Lardenoye [et al.] // Invest. Ophthalmol. Vis. Sci. 2000. Vol. 41. P. 4048-4053.
  3. 3. Use of scanning laser ophthalmoscope microperimetry in clinically significant macular oedema in type 2 diabetes mellitus / F. Mori [et al.] // Jpn. J. Ophthalmol. 2002. Vol. 46. P. 650-655.
  4. 4. Optical coherence tomography for evaluating diabetic macular oedema befor and after vitrectomy / P. Massin [et al.] // Am. J. Ophthalmol. 2003. Vol. 135. P. 169-177.
  5. 5. Diabetic macular oedema: risk factors and concomitans / J. M. Lopes de Faria [et al.] // Acta Ophthalmol. Scand. 1999. Vol. 77. P. 170-175.
  6. 6. The Wisconsin Epidemiologic Study of Diabetic Retinopathy XV / R. Klein [et al.] // Ophthalmology. 1995. Vol. 102. P. 7-16.
  7. Photocoagulation for diabetic macular edema. Early Treatment Diabetic Retinopathy Study report number 1 / Early Treatment Diabetic Retinopathy Study Research Group // Arch. Ophthalmol. 1985. Vol. 103. P. 1796-1806.
  8. Lee, C. M. Modified grid laser photocoagulation for diffuse diabetic macular edema. Long term visual results / C. M. Lee, R. J. Olk // Ophthalmology. 1991. Vol. 98. P. 1594-1602.
  9. Pathologic features of vascular endothelial growth factor-induced retinopathy in nonhuman primate / M. J. Tolentino [et al.] // Am. J. Ophthalmol. 2002. Vol. 133. P. 373-385.
  10. Angiotensin II and vascular endothelial growth factor in the vitreous fluid of patients with diabetic macular edema and other retinal disorders / H. Funatsu [et al.] // Am. J. Ophthalmol. 2002. Vol. 133. P. 537-543.
  11. Avery, R. L. Regression of retinal and iris neovascularization after intravitreal bevacizumab (Avastin) treatment / R. L. Avery // Retina. 2006. Vol. 26. P. 352-354.
  12. Intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration / R. L. Avery [et al.] // Ophthalmology. 2006. Vol. 113. P. 363-372.
  13. Intravitreal bevacizumab (Avastin) treatment of macular edema in central retinal vein occlusion: a short-term study / D. Iturralde [et al.] // Retina. 2006. Vol. 26. P. 279-284.
Contacts | ©Vitebsk State Medical University, 2007-2023